Value of urinary microalbumin test in cancer patients with borderline serum creatinine level
Keywords:Borderline creatinine, Cancer patients, Microalbumin, Urine
Background: Micralbuminuria (MA) is an early sign of incipient renal damage and cancer patients are at the risk of developing kidney diseases due to the use of nephrtoxic chemotherapeutic agents.
Methods: A pilot study of urinary microalbumin on 41 patients with borderline serum creatinine was carried out at regional cancer centre of North-East India during the period from June to August 2014. The patients whose serum creatinine levels were between 1.2 mg/dl to 1.3 mg/dl were considered as borderline for the present study. The assays were performed with a dimension Rxl max random access biochemistry analyzer.
Results: Out of 41 cases, 22 (53.6%) had MA, M:F = 1.75, <45 years 3 (13.6%) patients, in 45 years - 65 years 17 (77.2%) patients, and >65 years 2 (9.0%) patients were detected with urinary microalbumin. Chi square test showed P = 0.695 (Fisher’s exact P value).
Conclusion: Testing of urinary microalbumin can be done in cancer patients with borderline serum creatinine level in order to identify patients at risk of developing kidney disease.
Wang T, Wang Q, Wang Z, Xiao Z, Liu L. Diagnostic value of the combined measurement of serum Hcy, serum Cys C, and urinary microalbumin in type 2 diabetes mellitus with early complicating diabetic nephropathy. ISRN Endocrinol. 2013;2013:407452.
Aggarwal J, Kumar M. Prevalence of microalbuminuria among rural North Indian population with diabetes mellitus and its correlation with glycosylated haemoglobin and smoking. J Clin Diag Res. 2014;8:CC11-3.
Brott DA, Adler SH, Arani R, Lovick SC, Pinches M, Furlong ST. Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers. Drug Des Devel Ther. 2014;8:227-37.
Friedman AN, Marrero D, Ma Y, Ackermann R, Narayan KM, Barrett-Connor E, et al. Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre diabetic individuals. Diabetes Care. 2008;31:2344-8.
Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol. 2004;159:284-93.
Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension. Hypertension. 1997;30:1135-43.
Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990;300:297-300.
Shearman CP, Gosling P, Walker KJ. Is low proteinuria an early predictor of severity of acute pancreatitis? J Clin Pathol. 1998;42:1132-5.
Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes. 1992;41:736-41.
Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014;37:867-75.
Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes. 1998;47:793-800.
Chowta NK, Pant P, Chowta MN. Microalbuminuria in diabetes mellitus: Association with age, sex, weight, and creatinine clearance. Indian J Nephrol. 2009;19:53-6.
Palaniappan L, Carnethon M, Stephen P. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16:952-8.
Pedersen LM, Milman N. Microalbuminuria in patients with lung cancer. Eur J Cancer. 1998;34:76-80.
Estakhri R, Ghahramanzade A, Vahedi A, Nourazarian A. Serum Levels of CA15-3, AFP, CA19-9 and CEA tumor markers in cancer care and treatment of patients with impaired renal function on hemodialysis. Asian Pac J Cancer Prev. 2013;14:1597-9.